VarmX, a Dutch, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis, announced the publication in Nature Communications of a ground breaking LUMC study(1) on modified human factor X as a safe and effective reversal agent for prevention and treatment of bleeding in patients taking factor Xa oral anticoagulants.

AstraZeneca and Takeda Pharmaceutical Company Limited announced that they have entered an agreement to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).

InDex Pharmaceuticals Holding AB announced that the US FDA has granted orphan-drug designation for the drug candidate cobitolimod for treatment of ulcerative colitis in pediatric patients.

Eisai Co., Ltd. has announced that the results of a subpopulation analysis of patients with hepatitis B virus (HBV) coinfection in a Phase III trial of its in-house discovered and developed anticancer agent lenvatinib mesylate (product names: Lenvima / Kisplyx, "lenvatinib") versus sorafenib as a first-line treatment for unresectable HCC were presented for the first time during the 11th Annual Conference of the International Liver Cancer Association (ILCA) held in Seoul, South Korea.

Medtronic plc data announced reinforce the durability and safety of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD).

RIBOXX PHARMACEUTICALS, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and ACCINOV, a pharmaceutical establishment for experimental drug product announced the successful industrial GMP manufacturing, including packaging and quality control of RIBOXXIM®, a novel and highly potent Toll-like Receptor 3 (TLR3)-ligand.

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products announced it has entered into an exclusive agreement with US WorldMeds, LLC for the commercial manufacture of lofexidine.

Acasti Pharma Inc announced the achievement of a major corporate milestone by manufacturing the first cGMP batches of CaPre®, Acasti’s omega-3 pharmaceutical product candidate, produced with a proprietary and innovative continuous manufacturing process developed in partnership with CordenPharma.

Johnson Matthey, a global specialty chemicals company and provider of advanced process technologies, and Rennovia Inc., a privately held company that develops novel catalysts and processes for the cost advantaged production of chemical products from renewable feedstocks.

Intertek, a leading quality solutions provider to industries worldwide, has approved the ABB laboratory in Ratingen, Germany as the first Intertek SATELLITE™ Data Acceptance Program laboratory for ETL and ASTA.

Pharmapack Europe 2018 , Europe’s dedicated pharmaceutical packaging and drug delivery conference and exhibition, organised by UBM EMEA, is taking place on 7–8 February at Paris Expo Porte de Versailles, Paris.

A Spanish contract development and manufacturing organisation (CDMO) has expanded its GMP manufacturing offering with the installation of new automatic capsule filling capabilities at its EU-GMP approved plant in Pamplona, Spain.